April 27, 2023 by admin aurigene Oral Immune Checkpoint Antagonists Dually Targeting TIGIT and PD-1 pathways for Cancer Therapy
April 27, 2023 by admin aurigene Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
April 27, 2023 by admin aurigene Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
April 27, 2023 by admin aurigene Novel inhibitors of protein arginine methyltransferase 5 (PRMT5) for the treatment of solid tumors
April 27, 2023 by admin aurigene Preclinical in vivo evaluation of efficacy, pharmacokinetics and pharmacodynamics of novel PRMT5 inhibitors in multiple tumor models (PRMT5i)
April 27, 2023 by admin aurigene Targeting CD47- SIRPα interaction by novel peptide-based antagonists
April 27, 2023 by admin aurigene Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRPα axis (CD47 antagonists)
April 27, 2023 by admin aurigene Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway
April 27, 2023 by admin aurigene AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in
